Exercise and weight management without medication For patients who must discontinue GLP-1 therapy entirely due to cost, understanding the role of exercise alongside semaglutide provides context on how physical activity interacts with medication-assisted weight management
Extra caution is warranted for people with: Gastroparesis or delayed gastric emptying GLP-1 medications significantly delay gastric emptying and are generally not recommended in severe gastroparesis
Food & Drug Administration, FDA approves first oral GLP-1 treatment for type 2 diabetes (2019)
Diabetes Res Clin Pract 73: 107-110, 2006
spanning from 2005 to October 2023 utilized the Food and Drug Administration Adverse Event Reporting System (FAERS) to investigate patterns of suicidality associated with GLP-1 RA usage
Patients should be advised to seek prompt medical evaluation for severe or persistent gastrointestinal symptoms, vision changes, unusual neck swelling or hoarseness, or severe constipation with abdominal distention